Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,750, up 0.45% year-to-date, while the US Dow Jones fell by 0.58% [1][3] - The Chinese stock market saw gains, particularly in materials, consumer discretionary, and healthcare sectors, while energy and real estate lagged [3] Industry Insights - The Chinese pharmaceutical sector is experiencing a significant upward trend, with the MSCI China Healthcare Index rising 9.2% since early 2026, outperforming the MSCI China Index by 5.6% [4] - The trend of Chinese innovative drugs going overseas continues to gain momentum, with multiple business development (BD) transactions occurring in early 2026, indicating a strong market for overseas licensing [5] - Key transactions include the overseas rights granted by Rongchang Biopharma to AbbVie for RC148 and by Haisika for HSK39004, showcasing the clinical progress of these drugs [5] Company Analysis - China Ping An is projected to see a 12% increase in operating profit to RMB 135.9 billion in 2025, driven by improvements in life and health insurance segments [7] - The new business value (NBV) is expected to grow by 42% year-on-year to RMB 40.4 billion, with a strong performance anticipated in the first quarter of 2026, particularly in the bancassurance channel [8] - The target price for China Ping An has been raised to HKD 90, reflecting adjustments in profit and NBV growth forecasts, with the company currently trading at 0.71 times FY26E P/EV [8]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

Investment Rating - The report maintains a "Buy" rating for Ping An Insurance, with a target price raised to HKD 90 based on a sum-of-the-parts (SOTP) valuation [1][4]. Core Insights - The report highlights that the fourth quarter earnings may see relief amid growth stock corrections, with expectations of a 12% year-on-year increase in group OPAT for 2025, reaching RMB 136 billion, and a 5.1% increase in net profit to RMB 133 billion [1][3]. - The insurance company is projected to achieve double-digit growth in NBV (New Business Value) in 2026, driven by strong first-year premium growth and stable profit margins [2][4]. Summary by Sections Financial Performance - For FY25, the net profit is expected to be RMB 162.5 billion, with EPS projected at RMB 7.52, reflecting a 5.1% year-on-year increase [5][13]. - The report provides a detailed financial summary, indicating a steady increase in net profit and EPS over the forecast period, with net profit reaching RMB 175.7 billion by FY27 [5][15]. Valuation Metrics - The target price of HKD 90 implies a valuation of 0.9 times the FY26E price-to-earnings ratio and 1.24 times the price-to-book ratio [4][14]. - The report employs a comprehensive valuation method, indicating a fair value for various segments, including life insurance and property & casualty insurance, contributing to the overall target price [4][14]. Business Growth Drivers - The report notes that the bank's insurance channel is expected to benefit from a shift in household deposits, with a projected 18% growth in NBV for FY26 [2][4]. - The strong performance in the insurance sector is supported by robust underwriting profits and improved investment service results, particularly in the context of a recovering capital market [1][3].

Investment Rating - The report initiates coverage on 康龙化成 with a "Buy" rating and a target price of 38.08 RMB, indicating a potential upside of 21.7% from the current price of 31.30 RMB [1][3]. Core Insights - 康龙化成 is recognized as a leading integrated CXO company in China, established in 2004, providing comprehensive services throughout the drug development lifecycle. The company is expected to benefit from the growing global demand for pharmaceutical R&D outsourcing [1][7]. - The report highlights the company's strategic expansion into various sectors, including small molecule CDMO, clinical development, and large molecule & cell and gene therapy (CGT), which positions 康龙化成 as a competitive player in the global market [7]. - The company is projected to achieve revenue growth rates of 14.2%, 14.8%, and 16.3% for FY25E, FY26E, and FY27E, respectively, with adjusted net profit growth rates of 12.3%, 17.8%, and 18.7% for the same periods [7][11]. Financial Summary - For FY23A, 康龙化成 reported sales revenue of 11,538 million RMB, with a year-on-year growth of 12.4%. The adjusted net profit for the same period was 1,903 million RMB, reflecting a growth of 3.8% [2][11]. - The company’s sales revenue is expected to reach 14,022 million RMB in FY25E, with a projected growth of 14.2% year-on-year [2][11]. - The adjusted net profit is forecasted to be 1,804 million RMB in FY25E, with a year-on-year increase of 12.3% [2][11]. Shareholder Structure - The shareholder structure indicates that 19.3% of the shares are held by Hong Kong investors, while the actual controller holds 17.7% [4]. Stock Performance - The stock has shown a 1-month absolute return of 8.6% and a 6-month return of 15.1%, indicating positive market sentiment [5].

Investment Rating - The report initiates coverage on 康龙化成 (300759 CH) with a "Buy" rating and a target price of 38.08 RMB, indicating a potential upside of 21.7% from the current price of 31.30 RMB [1][3]. Core Insights - 康龙化成 is recognized as a leading integrated CXO service provider in China, benefiting from the growing global demand for pharmaceutical R&D outsourcing. The company offers end-to-end services across the entire drug development lifecycle, positioning itself to capitalize on the increasing outsourcing needs in the pharmaceutical industry [1][7]. - The report highlights the company's strategic expansion into small molecule CDMO, clinical development, and large molecule & cell and gene therapy (CGT) sectors, creating a comprehensive one-stop CXO platform that reduces operational risks and costs for clients [7]. - The company is expected to see revenue growth of 14.2% in 2025, 14.8% in 2026, and 16.3% in 2027, with adjusted net profit growth projected at 12.3%, 17.8%, and 18.7% for the same years [7][8]. Financial Summary - For FY23A, 康龙化成 reported sales revenue of 11,538 million RMB, with a year-on-year growth of 12.4%. The adjusted net profit for the same period was 1,903 million RMB, reflecting a growth of 3.8% [2][11]. - The company’s sales revenue is projected to reach 14,022 million RMB in FY25E, with a corresponding adjusted net profit of 1,804 million RMB, indicating a year-on-year increase of 12.3% [2][11]. - The adjusted earnings per share (EPS) for FY25E is estimated at 1.01 RMB, with a forward P/E ratio of 30.8 times [2][11]. Shareholder Structure - The shareholder structure indicates that 19.3% of the shares are held by Hong Kong investors, while the actual controller holds 17.7% [4]. Stock Performance - The stock has shown a 1-month absolute return of 8.6% and a 6-month return of 15.1%, outperforming the market in these periods [5].

Group 1: Market Overview - Global stock markets showed mixed performance, with the Hang Seng Index closing at 26,630, up 0.17% for the day and 3.90% year-to-date [1] - The Shanghai Composite Index rose by 0.14% to 4,123, while the Shenzhen Composite Index increased by 0.69% to 2,714, reflecting a positive trend in the Chinese market [1] - The US markets also experienced gains, with the Dow Jones up 0.63% and the S&P 500 up 0.55%, indicating a favorable environment for equities [1] Group 2: Sector Performance - In the Hong Kong market, the real estate sector led gains with a 1.62% increase, while the financial sector saw a decline of 0.37% [2] - The energy, real estate, and public utilities sectors in Hong Kong outperformed, while materials, healthcare, and information technology sectors lagged [3] - The A-share market saw significant gains in construction materials, defense, and oil & petrochemicals, while beauty care, banking, and pharmaceuticals underperformed [3] Group 3: Company Analysis - 康龙化成 (300759 CH) - 康龙化成 is recognized as a leading integrated CXO service provider in China, offering comprehensive drug development services [4] - The company is expected to benefit from the growing global demand for pharmaceutical R&D outsourcing, with a target price set at 38.08 RMB and a "buy" rating [4][8] - The company has established a one-stop CXO service platform, significantly reducing operational risks and costs for clients, which is crucial in the current biopharmaceutical landscape [4] Group 4: Business Growth and Projections - 康龙化成's laboratory services are projected to see over 15% growth in new orders in 2024, providing a solid foundation for revenue [5] - The small molecule CDMO segment is expected to grow over 35% in new orders in 2024, driven by commercialized projects [5] - The company anticipates revenue growth of 14.2% in 2025, with non-IFRS net profit expected to increase by 12.3% [8]

Investment Rating - The report maintains a "BUY" rating for iQIYI, indicating a potential return of over 15% over the next 12 months [16]. Core Insights - iQIYI is expected to see a recovery in both revenue and earnings in 4Q25, with total revenue projected to grow by 2% year-over-year (YoY) and 1% quarter-over-quarter (QoQ) to RMB6.77 billion, driven by the recovery of membership and content distribution businesses [1][8]. - The forecast for non-GAAP net income in 4Q25 is RMB93 million, a significant improvement from the non-GAAP net losses recorded in previous quarters [1]. - The target price for iQIYI has been adjusted to US$2.75, based on an 18x multiple of the 2026E non-GAAP EPS, reflecting a 36.8% upside from the current price of US$2.01 [3][11]. Financial Performance Summary - Revenue for FY23A was RMB32,018 million, with a YoY growth of 10.4%. However, FY24A revenue is expected to decline by 8.7% to RMB29,225 million, followed by a further decline of 6.7% in FY25E to RMB27,263 million [2]. - The adjusted net profit for FY23A was RMB2,984.1 million, which is expected to drop to RMB1,512.2 million in FY24A and further to RMB264.1 million in FY25E [2]. - Gross margin is projected to decrease from 27.8% in FY23A to 20.9% in FY25E, before recovering to 23.3% in FY26E and 24.2% in FY27E [2]. Business Forecasts and Valuation - iQIYI's revenue for FY25E is forecasted at RMB27.3 billion, with a slight increase in FY26E to RMB27.9 billion and FY27E to RMB28.4 billion [9]. - The non-GAAP net profit is expected to significantly improve from RMB0.3 billion in FY25E to RMB1.0 billion in FY26E and RMB1.3 billion in FY27E, reflecting a recovery trend [9]. - The valuation of iQIYI is based on a target PE multiple of 18x for 2026E non-GAAP EPS, which is at a discount to the sector average of 24x due to intense competition in the video streaming sector [11].

Group 1: Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,585, up 0.37% for the day and 3.72% year-to-date [1] - The US markets also experienced gains, with the Dow Jones up 1.21% and the S&P 500 up 1.16% [1] - In contrast, the German DAX and Japanese Nikkei 225 saw declines of 0.58% and 0.41% respectively [1] Group 2: Sector Performance - In the Hong Kong market, the Hang Seng Financial sector fell by 0.44%, while the Hang Seng Utilities sector rose by 1.15% [2] - The real estate sector underperformed, with a decline of 0.77% year-to-date [2] - The industrial sector showed resilience, gaining 0.86% for the day [2] Group 3: Company Insights - iQIYI is projected to see a revenue recovery in Q4 2025, with expected total revenue of RMB 6.77 billion, reflecting a 2% year-on-year growth [4] - The company is anticipated to achieve a non-GAAP net profit of RMB 93 million, a turnaround from previous losses [4] - iQIYI's innovative business segments, including overseas operations and IP derivatives, are showing positive progress [4]

Group 1: Report Industry Investment Rating - No relevant content found Group 2: Core Views of the Report - The new SHUION 29 rose 0.6pt from RO at 98.423 yesterday, while the existing SHUION 26 retraced 0.2pt [2] - KUAISH 31 - 36s and TW lifers tightened 1 - 3bps this morning, and FUTLAN 28/VLLPM 29 rose 0.6 - 0.9pt [3] - In 2025, the cumulative contracted sales of 31 Chinese developers dropped 21.5% yoy to RMB1,757.6bn [3][8] - A new round of demand - driven stimulus on the property market may come in 1Q26, but the recovery will likely remain slow due to weak homebuyers' confidence [9] - CMBI economic research expects a 10bp cut in LPR in 1Q26, followed by an additional 10bp LPR cut in 3Q26, which should support the weak housing market [9] Group 3: Summary by Related Catalogs Trading Desk Comments - Yesterday, new issues like KUAISH 31 - 36s tightened 2bps earlier in the day but closed unchanged, and TW lifers closed 2 - 5bps wider [2] - In Greater China, beta IG name ZHOSHK 28 closed 1bp wider, and CHIOIL 26 was 0.1pt lower [2] - In HK, FAEACO 12.814 Perp rose 1.1pts, while LIFUNG 5.25 Perp dropped 2.8pts [2] - In Chinese properties, LNGFOR 27 - 32 were 0.4pt lower to 0.3pt higher, and FUTLAN 28/FTLNHD 26 - 27 were unchanged to 0.3pt lower [2] - In KR, financial and corporate names faced selling pressure, with spreads widening 1 - 3bps [2] - In JP, 10yr bonds NTT 35/MUFG 35 - 36s/SOBKCO 35/SMBCAC 35/TACHEM 35 were 5 - 6bps wider [2] - In SE Asia, BBLTB/OCBCSP T2s widened 1 - 6bps, and TOPTB 6.1 Perp/IHFLIN 27 - 30s was 0.1pt lower [2] - In the Middle East, KSA/QATAR long - end bonds were down 0.3 - 0.5pt [2] - In the overall IG FRN space, lower - beta names were 1 - 2bps wider [2] Macro News Recap - On Tuesday, S&P (-2.06%), Dow (-1.76%), and Nasdaq (-2.39%) were lower, triggered by Trump's Greenland tariff threat and Japan's political situation [6] - UST yield was higher on Tuesday, with 2/5/10/30 year yield at 3.60%/3.86%/4.30%/4.91% [6] Desk Analyst Comments - In Dec'25, 31 developers reported contracted sales of RMB186.2bn, a 15.3% yoy decrease from RMB219.9bn in Dec'24 [7] - Only 2 out of 31 developers reported yoy increase in contracted sales in 2025: CHJMAO and GRNLGR with 16% and 7% increases respectively [8] - The bottom performers in 2025 were GEMDAL, JINGRU, and CIFIHG, with their contracted sales dropping 56%, 55%, and 52% yoy respectively [8] Offshore Asia New Issues (Priced) - The Republic of the Philippines issued 500mn/1500mn USD bonds with 5.5yr/10yr tenors, 4.25%/5.0% coupons, and issue ratings of Baa2/BBB+/BBB [11] - Toyota Finance Australia issued bonds with various tenors and coupons, including a 3.25yr bond at SOFR + 60 and a 25yr bond at 5.75% [11] - Woori Bank issued 300mn/300mn USD bonds with 3yr/5yr tenors, SOFR + 48/4.125% coupons, and an issue rating of A1/A+/- [11] Offshore Asia New Issues (Pipeline) - Korea Development Bank plans to issue bonds with 3yr/5yr/5yr/10yr tenors and coupons like SOFR + 41/SOFR + 52/SOFR Equiv/SOFR + 70, with an issue rating of Aa2/AA/AA - [12] News and Market Color - Yesterday, 93 credit bonds were issued onshore with an amount of RMB84bn, and month - to - date, 1,134 credit bonds were issued with a total amount of RMB934bn, a 24.5% yoy decrease [13] - China Oil & Gas postponed its USD Reg S 3NC2 bond offering due to market volatility [3][13] - Seazen Group agreed to sell Seazen Resources Securities for HK 62.8mn [13]

招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 行业点评 2026 年 1 月 21 日 全球市场观察 招银国际研究部 邮件：research@cmbi.com.hk | 环球主要股市上日表现 | | | | | --- | --- | --- | --- | | | 收市价 | | 升跌（%） | | | | 单日 | 年内 | | 恒生指数 | 26,488 | -0.29 | 3.34 | | 恒生国企 | 9,095 | -0.43 | 2.03 | | 恒生科技 | 5,683 | -1.16 | 3.04 | | 上证综指 | 4,114 | -0.01 | 3.65 | | 深证综指 | 2,678 | -0.83 | 5.80 | | 深圳创业板 | 3,278 | -1.79 | 2.34 | | 美国道琼斯 | 48,489 | -1.76 | 0.88 | | 美国标普 500 | 6,797 | -2.06 | -0.71 | | 美国纳斯达克 | 22,954 | -2.39 | -1.24 | | 德国 DAX | 24,703 | -1.03 | 0.87 | | 法 ...